The next generation in patient-specific immunotherapeutic cancer vaccines BioVaxys is a biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma, ovarian cancer, and other solid tumor types.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/biovaxys-llc” connections=”true” suffix=””]
BioVaxys vaccines are created by extracting a patients own (e.g. Çautologous) cancer cells, chemically treating them with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic. BioVaxys lead clinical program is to develop the autologous bihaptenized vaccine together with an anti-CTLA4 or anti- PDA checkpoint antibodies for melanoma and ovarian cancer.
In July 2018, BioVaxys and Thomas Jefferson University, a Philadelphia-based professional university; entered into an exclusive worldwide license agreement for a technology comprising highly-targeted, patient-specific, immunotherapeutic vaccines to treat ovarian cancer, melanoma, and other solid tumor types.